|Bid||0.4820 x 0|
|Ask||0.5100 x 0|
|Day's Range||0.4820 - 0.4820|
|52 Week Range||0.1590 - 0.7150|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Canntab Therapeutics Limited. (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) ("Canntab" or the "Company"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the "Offering") of secured convertible debentures of the Company ("Convertible Debentures"), pursuant to which the Company issued Convertible Debentures for gross proceeds of $1,575,000 (the "Convertible Debentures"). The ...
QUÉBEC CITY, Nov. 28, 2020 /CNW Telbec/ - The most recent data on the evolution of COVID-19 in Québec show 1,480 new cases, bringing the total number of people infected to 139,643.
Toronto, Ontario--(Newsfile Corp. - November 16, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.During a time ...